Profile and Predictors of Blood Tumor Mutational Burden in Advanced Hepatocellular Carcinoma

Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Franses, Joseph W, Lim, Mir, Burgoyne, Adam M, Mody, Kabir, Lennerz, Jochen, Chang, Jeremy, Imperial, Robin, Dybel, Stacey N, Dinh, Thi M, Masannat, Jude, Weipert, Caroline M, Hsiehchen, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632309/
https://www.ncbi.nlm.nih.gov/pubmed/36103364
http://dx.doi.org/10.1093/oncolo/oyac189
Descripción
Sumario:Advanced hepatocellular carcinoma (HCC) is responsive to immune checkpoint inhibitors, but there are currently no known biomarkers to predict treatment benefit. Blood TMB (bTMB) estimation via circulating tumor DNA (ctDNA) profiling can provide a convenient means to estimate HCC TMB. Here we provide the first landscape of bTMB in advanced HCC using a commercially available next-generation sequencing assay, show that it is approximately three times as high as matched tissue TMB, and show that bTMB correlates with NAFLD cirrhosis etiology and the presence of genomic alterations in HTERT and TP53. These results lay the foundation for subsequent studies evaluating bTMB as an immune therapy predictive biomarker in HCC.

Ejemplares similares